ライフサイエンスコーパス: study entry

1 ischaemic attack) or a further ICH following study entry.

2 end of study, or most cognitive measures at study entry.

3 experienced depression within 2 years after study entry.

4 ime scale can be set to start at birth or at study entry.

5 .5) predictions at participant residences at study entry.

6 aving an eosinophil count of 2% or higher at study entry.

7 ibitors or ARBs, for at least 8 weeks before study entry.

8 ession by RECIST criteria within 7 months of study entry.

9 or sham based on prior treatment for DME at study entry.

10 ll women had an intact uterus at the time of study entry.

11 o 34, 35 to 44, and 45 to 65 years of age at study entry.

12 ard health questionnaire were carried out at study entry.

13 th antipsychotics did not exceed 6 months at study entry.

14 0 IU/m(2) weekly), beginning at week 7 after study entry.

15 tients had infradiaphragmatic involvement at study entry.

16 were positive for meningococcal carriage at study entry.

17 or CRC who were not adherent to screening at study entry.

18 outcome was CRC screening within 6 months of study entry.

19 a median duration of epilepsy of 25 years at study entry.

20 Criteria in Solid Tumors version 1.1) before study entry.

21 gic failure was associated with higher VL at study entry.

22 a sample of the cohort members enumerated at study entry.

23 rospectively over the 18-month period before study entry.

24 ervation, 722 (21%) were age </= 40 years at study entry.

25 l consistency, was initially administered at study entry.

26 associated with fasting insulin measured at study entry.

27 othelin-receptor antagonists, was allowed at study entry.

28 phase FISH (iFISH) analysis was performed at study entry.

29 0.37 years (range, 0.23 to 0.6 years) before study entry.

30 rticipants reported moderate to severe HF at study entry.

31 Denmark before their 18th birthday or before study entry.

32 or immunosuppressive therapy was allowed at study entry.

33 -two patients (27%) were age >/= 70 years at study entry.

34 mortality had participants initiated ART at study entry.

35 59.8 +/- 11.5 y) underwent (18)F-FDG PET at study entry.

36 point was disease remission at 6 months from study entry.

37 er causes occurring fewer than 120 days from study entry.

38 emoved and without clinical signs of BCRL at study entry.

39 te (MTX) or with substantial MTX toxicity at study entry.

40 munizations, with a boost 6 to 8 months from study entry.

41 gimens), and 45% had extrahepatic disease at study entry.

42 free of cancer and cardiovascular disease at study entry.

43 All patients had progressive disease before study entry.

44 progressing from dexamethasone treatment at study entry.

45 onsuming low-, medium-, and high-ED diets at study entry.

46 were at least 70 years of age at the time of study entry.

47 (1c)) measurements taken in the years before study entry.

48 r participants with no injurious violence at study entry.

49 lence of cervical HPV infection was 25.6% at study entry.

50 progression at a median of 43.4 months from study entry.

51 owering therapy and myocardial infarction at study entry.

52 idney diseases that were already underway at study entry.

53 sults; PD-L1 positivity was not required for study entry.

54 at was frequency matched by decade of age at study entry.

55 EA) BI and non-BI strains of C. difficile at study entry.

56 ntagonists, or had no follow-up visits after study entry.

57 omen attempting pregnancy for </=6 cycles at study entry.

58 ory of artificial tear use within 30 days of study entry.

59 lergic disease and had no eczema symptoms at study entry.

60 disease recurrence or metastatic disease at study entry.

61 rgical revascularisation in the month before study entry.

62 atory cells from tumour biopsies provided at study entry.

63 ompared with subjects with low VWF levels at study entry.

64 ere determined in plasma samples obtained at study entry.

65 s of whole blood during the 3 days following study entry.

66 an rCBV than nontransformers at the point of study entry (1.93 vs 1.31).

67 6%) of the cohort died during follow-up from study entry (10 years after cure).

68 The BMI was calculated at the time of study entry (12 to 18 weeks of gestation).

69 Assessments were done at study entry, 12 months, and 24 months.

70 ng 1495 patients was 53 years at the time of study entry; 157 (11%) had axillary node-negative diseas

71 em food frequency questionnaire completed at study entry (1995-1996) with the MyPyramid Equivalents D

72 ho had received more than 6 months of ADT at study entry (3.7% v 2.0%; P = .0645).

73 tinuous remission in progress at the time of study entry; (3) receiving self-, parent-, or caregiver-

74 utum smears and 43% had cavitary disease; at study entry, 35% remained smear positive after a median

75 At study entry, 350 boys had serum OCPs measured.

76 02.4 mum vs 397.6 +/- 96.5 mum, P = 0.002 at study entry; 381.2 +/- 106.6 mum vs 364 +/- 101.2 mum, P

77 Participants' mean age was 58 years at study entry; 42% were non-Hispanic black, and 13% were H

78 ion Study were followed up for 5 years after study entry (44.6% of the original Treatment for Adolesc

79 talized for heart failure in the year before study entry (47% vs. 28%, p = 0.004) and had a higher in

80 pants (6103 screening studies; median age at study entry, 54.0 years; range, 25-91 years), 1454 had u

81 tients (175 men and 166 women; median age at study entry, 62 years) in the 1-year group and 60 years

82 At study entry, 64% of subjects had VWF antigen (VWF:Ag) or

83 nts were receiving concomitant treatments at study entry, 69 of whom attempted to reduce them; 65% (4

84 In the year after study entry, 84.8% of women (n = 173) returned for a sub

85 d GIST and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.

86 ed at AIDs Clinical Trial Group (ACTG) A5230 study entry, a study of lopinavir/ritonavir (LPV/r) mono

87 ents), about 17% were older than 50 years at study entry, about 50% were non-white, and about 80% wer

88 onship between pollutants and measured BP at study entry, adjusting for cardiovascular disease risk f

89 However, we discontinued study entry after five serious adverse events were obser

90 ician performed tympanometry and otoscopy at study entry, after 3 and 7 days, and then weekly until b

91 and brain magnetic resonance (MR) imaging at study entry, after the first 12-week period, and at stud

92 Median levels of NT-proBNP were higher at study entry among incident cases (120.3 ng/l [interquart

93 ted C-peptide concentration >/=0.2 nmol/L at study entry among subjects with up to a 5-year diabetes

94 V adenocarcinoma diagnosed > 6 months before study entry and 1 prior systemic therapy were randomly a

95 in this analysis, 34 receiving apheresis at study entry and 14 younger than 18 years.

96 ontrast visual acuity, and SD OCT imaging at study entry and 3 and 6 months.

97 psies of 45 patients with CMT1A, obtained at study entry and after 24-months of treatment either with

98 At study entry and after 5 years, clinical and MRI (ie, gra

99 nd Self-Rated Health scales were assessed at study entry and annually thereafter; linear mixed models

100 lmologic examination, including swept-OCT at study entry and at 7 days and 30 days after treatment wi

101 keratometry reading (Kmax) were measured at study entry and at the 12-month follow-up.

102 cale (GSRS) was completed by all patients at study entry and by treatment-naive patients after PPI th

103 lmonary TB treated at least 12 months before study entry and considered cured.

104 Cognition Study who did not have dementia at study entry and developed incident dementia during follo

105 nt follow-up was 11.8 years (IQR 17-26) from study entry and did not differ between countries.

106 al menopause) who were 40-98 years of age at study entry and did not have a history of breast cancer.

107 individual propensity scores for MTX use at study entry and during followup in a time-varying manner

108 At study entry and every 3 months through 2 years, particip

109 cholesterol and use of CLM were measured at study entry and every 6 months up to 5.5 years.

110 number of hospital visits, and time between study entry and exit.

111 orted dieting at study entry were heavier at study entry and gained more weight over time than did no

112 Complications Study who were free of CAD at study entry and had DNA available were selected (n = 453

113 idepressant use or mania symptom load at the study entry and mania or depression symptom severity at

114 fidaxomicin, and 44 received vancomycin) at study entry and on days 4, 10, 14, 21, 28, and 38 for qu

115 ive individuals who reported no prior ART at study entry and provided plasma samples, 1328 individual

116 d functional assessments were carried out at study entry and repeated annually over a 3-year observat

117 rne SPCs and the cellular content of HIFs at study entry and the first-week follow-up visit predicted

118 Participants self-reported alcohol use at study entry and then again after 15, 20, and 25 years.

119 1,831 subjects who did not have dementia at study entry and then did or did not develop incident dem

120 Echocardiograms were obtained 1 year after study entry and then every 2 years; BP was measured annu

121 stula vs. graft) in hemodialysis patients at study entry and time from placement until primary and se

122 als for patients with more severe disease at study entry and to worsen for patients with less severe

123 improve in those with more severe disease at study entry and to worsen in those with less severe dise

124 Clinical features at study entry and treatment outcomes were evaluated in pat

125 fee-for-service insurance coverage prior to study entry and using either a fixed-window or all-avail

126 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression.

127 Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and C

128 Among subjects without depression at study entry and without dementia or significant cognitiv

129 children with diabetes (4-10 years of age at study entry) and 69 age-matched control subjects at two

130 ard operating procedures, fixed criteria for study entry, and common reagents, to optimize combined a

131 ypercortisolism for a minimum of 10 years at study entry, and continuing to be cured with no relapses

132 tched by age, sex, race/ethnicity, timing of study entry, and sample selection.

133 progressive brain metastases at the time of study entry; and those with leptomeningeal disease.

134 Remission, defined as the absence of all study entry anxiety disorders.

135 Ages at milestones that occur prior to study entry are left censored if individuals are enrolle

136 ts in 19 IRIS and 39 control participants at study entry, ART initiation, and IRIS and used condition

137 At study entry at average age of 10 years, residential near

138 the clinic visit closest to 12 months after study entry) at the patient and clinic levels.

139 ge-bowel biopsy samples from the patients at study entry, at completion of 8 weeks of blinded therapy

140 enal function measured in the 2 years before study entry, based on at least three measurements over a

141 th MRI scans of the brain and spinal cord at study entry (baseline) and after 1 and 3 years.

142 ess and macular volume were assessed once at study entry (baseline) by optical coherence tomography (

143 ma exacerbations within the 12 months before study entry, baseline asthma medications, geographic reg

144 nts with no history of injurious violence at study entry, baseline noninjurious violence was the stro

145 Baseline study entry BCVA was 20/63 and was maintained at 20/62 a

146 b infusions, at 6 and 8 weeks (14 weeks from study entry) before initiating another DMT.

147 There were no significant differences at study entry between the rituximab and placebo groups.

148 specialist shoulder clinician 3 months after study entry, but no intervention).

149 Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49

150 tection of NVP resistance in plasma virus at study entry by standard population genotype was strongly

151 window could retrospectively be predicted at study entry by the ability of CD8(+) T cells to gain acc

152 ed pressure wave, and reservoir pressure) at study entry compared with subjects without improvement (

153 The independent variables, assessed at study entry, comprised participants' recent injurious an

154 definitions of low testosterone varied, and study entry criteria varied.

155 A total of 491 patients met study entry criteria with 353 IH cases and 138 OH cases.

156 age, 80.1 years [10.7], 70.5% women) who met study entry criteria, overall mortality at 30 days was 7

157 after giving informed consent and fulfilling study entry criteria.

158 A total of 16,527 patients met all study entry criteria.

159 spite the reliance on behavioral measures as study entry criteria.

160 One hundred thirty-eight cases met study entry criteria; the overall mortality was 62% (85

161 tients who had a qualifying infection as per study-entry criteria, received study drug, did not recei

162 llow-up scans in 5 PDD subjects at 2 y after study entry demonstrated a significant interval within-s

163 ex, blood pressure, and diabetes mellitus at study entry did not have a large effect on these estimat

164 rd deviation; SD) duration between prior and study entry dose was 199.4 (156.0) days, and 91 (36.4%)

165 l-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission.

166 tricular ejection fraction (LVEF) >/= 55% at study entry following neoadjuvant chemotherapy with or w

167 t coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AI

168 udy and 1076 individuals < or = 50 of age at study entry from the Multi-Ethnic Study of Atheroscleros

169 At study entry, gray lesion was associated with exudative f

170 Subjects whose VWF testing was normal at study entry had a similar rate of sequence variations as

171 Compared with controls, patients with CDI at study entry had counts of major microbiome components th

172 or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 de

173 sed risk of recurrent HGAIN at 2 years after study entry (HR .47; 95% CI, .22-1.00; P = .05).

174 sed risk of recurrent HGAIN at 2 years after study entry (HR 4.06; 95% confidence interval [CI], 1.58

175 n-genetic mortality risk factors measured at study entry (i.e., middle age for most participants).

176 d to controls, cases displayed elevations at study entry in interleukin (IL) 8, T-helper (Th) 1 (IL-2

177 In addition, PET scores at study entry in MCI patients significantly predict clinic

178 BMC samples from 181 maraviroc recipients at study entry in MOTIVATE or A4001029 (51% R5 by original

179 tandard genotype were detected more often at study entry in NNRTI-experienced patients than NNRTI-nai

180 prostate cancer diagnosis and mortality from study entry (in waves from 1967 to 1987) through 2009.

181 ssociation functional class I/II symptoms at study entry, including 249 in whom left ventricular outf

182 47 of 72 patients not on apheresis at study entry increased evolocumab dosing to every 2 weeks

183 Reduced reward learning at study entry increased the odds of a persisting diagnosis

184 igen SOX2 and preserved humoral responses at study entry independently correlated with reduced risk o

185 Ciprofloxacin used at study entry independently predicted invasive Candida inf

186 men with CH-B (n = 337) or CH-C (n = 343) at study entry into the MACS were prospectively followed to

187 iodine concentration (UIC) were assessed at study entry (<20 weeks' gestation) and at 28 weeks' gest

188 iovascular risk factors and comorbidities at study entry (mean [SD], 8.57 [6.55] years after transpla

189 At study entry, mean age of the children was 5.3 years.

190 At study entry, mean choroidal thickness measured in the ce

191 beta-HPV DNA positive, with 1 to 13 types at study entry (median, 4.0 types).

192 oon after HIV-1 infection, from the level at study entry (median, 495 cells per cubic millimeter; int

193 At study entry, median age was 11 months (interquartile ran

194 At study entry, median BLL was 3 mug/dL (range, < 0.5-31 mu

195 At study entry, median body mass index was high (29.2 kg/m(

196 At study entry, median maternal age was 28 y (interquartile

197 bin and phosphorus, and log(10) M30 value at study entry most accurately identified patients who woul

198 After study entry (n = 1866), parents of eligible infants (n =

199 ty outcomes among those with moderate CKD at study entry (n = 3,267) with those with baseline eGFR >o

200 Men with </= 6 months of ADT at study entry (n = 36) had a greater rate of decrease in L

201 itive urine drug or breath alcohol screen at study entry (N=228) (odds ratio=2.18, 95% CI=1.30, 3.68)

202 At study entry, NIH skin score 3 and Lee skin symptom score

203 Study entry OCT values were similar in both treatment gr

204 s virus envelope glycoproteins enabled us to study entry of viruses that exploit diverse internalizat

205 udotyping is a useful and safe technique for studying entry of emerging strains of influenza virus.

206 rty-nine vaccine recipients were assessed at study entry; on the day of the third vaccination; at 24

207 s 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22.

208 survival (OS) were assessed from the date of study entry or random assignment, as appropriate.

209 213 participants who received ART soon after study entry or sometime thereafter and had a suppressed

210 At study entry, participants estimated the age at which the

211 on, formal education, clinical diagnosis for study entry, patient history, and concomitant medication

212 At study entry, patients were stratified according to the s

213 Although at study entry, patients with PaO2/FIO2 less than 150 had a

214 me dose and schedule as last received before study entry, plus cetuximab 400 mg/m2 loading dose, then

215 14 were recruited, with the first FRI as the study entry point.

216 Brain-PAD at study entry predicted time-to-disability progression (ha

217 s between trough tacrolimus concentration at study entry (r=-0.56; P=0.01) and 3-month tacrolimus exp

218 atment; 6 eyes without exudative features at study entry received deferred treatment (after 1 month o

219 Twenty-four eyes with exudative features at study entry received prompt treatment; 6 eyes without ex

220 ith microscopic or gross residual disease at study entry received RT.

221 Study entry required hospitalization within the previous

222 ults 40 years and older vs < 40 years old at study entry, respectively), and participants who were no

223 on, and the TNF pathway were measured in the study entry samples.

224 x (-5%) and hippocampus (-3%), compared with study entry scans.

225 Analyses in women age 50 years or older on study entry showed benefits of clodronate for recurrence

226 At study entry, significant differences between groups were

227 FcepsilonRIalpha mRNA expression measured on study entry significantly improved an existing model of

228 ts, and 8 of 9 participants receiving FIX at study entry stopped prophylaxis.

229 y excluding participants who had dementia at study entry, subsequently developed dementia during the

230 accounting for important variables known at study entry such as tumor location and histology, female

231 destly elevated brain beta-amyloid burden at study entry, suggesting plasma NT1 levels capture very e

232 Of the 177 patients who met the criteria for study entry, the majority were women (80%) and African A

233 .8%] African American) aged 5 to 19 years at study entry, the mean age of peak height velocity was 13

234 At study entry, the mean age of the children was 12 months

235 At study entry, the mean MRSS value was 21.0 in the D-Pen T

236 At study entry, the mean time on dialysis among recipients

237 At study entry, the median HIV viral load was 12,759 copies

238 When results were stratified by age at study entry, the risk of AD was only significantly incre

239 At study entry there was no significant difference in CSF o

240 At study entry these patients had reduced CSF amyloid Ass1-

241 re not receiving corticosteroid treatment at study entry; those in cohort B were symptomatic and on a

242 se CNS disease is radiographically stable at study entry; those with active brain metastases, defined

243 t limitation were proxy appointment prior to study entry (time of tracheotomy/RCU transfer) (odds rat

244 olinium-enhancing lesions (metformin, 1.8 at study entry to 0.1 at month 24; pioglitazone, 2.2 at stu

245 try to 0.1 at month 24; pioglitazone, 2.2 at study entry to 0.3 at month 24).

246 w or enlarging T2 lesions (metformin, 2.5 at study entry to 0.5 at month 24; pioglitazone, 2.3 at stu

247 try to 0.5 at month 24; pioglitazone, 2.3 at study entry to 0.6 at month 24), as well as of gadoliniu

248 From study entry to 18 months before RRT, GFR declined 7% fas

249 of 18 +/- 30 (median 10) in the year before study entry to 2.0 +/- 4.3 (median 0) at a median follow

250 treatment interval increased from 35 days at study entry to 63 days at 12 months and was 60 days at 3

251 m was conducted at 6 and 12 months following study entry to assess for infection.

252 Mean changes in CASI Z scores from study entry to assessment at years 1 (n=2472), 2 (n=1968

253 ants were analyzed by allele-specific PCR at study entry to quantify NVP-resistant mutants down to 0.

254 Relapsed/refractory disease at study entry, TP53 aberration, advanced Rai stage, and hi

255 l endpoints such as survival time (time from study entry until death).

256 in (TBP) measured by neutron activation from study entry until immediately prior to LT was the primar

257 asma or serum candidate proteins measured on study entry using Myriad-RBM multiplex panels.

258 xis II comparison subjects) were assessed at study entry using the cognitive section of the Revised D

259 olony-forming units [CFU]) of 6.7 +/- 2.0 at study entry; vancomycin treatment consistently reduced C

260 At study entry, viral etiology, rhinovirus genome load, ato

261 e most recent syphilis episode for which the study entry visit was performed within 30 days of the sy

262 ce mutation associations with subtype, site, study entry VL, and CD4 were evaluated using Fisher exac

263 The LVEF at study entry was 0.35 +/- 0.10, 0.51 +/- 0.11 at 6 months

264 Median overall survival from study entry was 5.7 months (range, 0.7 to 28+ months).

265 Mean age at study entry was 63.4 years (SD 8.6).

266 The median age at study entry was 64.5 years (range, 49.8 to 80.9 years).

267 The median BDI-II score at study entry was 8, with 28% of the sample having BDI-II

268 HF hospitalization within 2 years of study entry was associated with greater adjusted risks f

269 cogenic HPV genotypes within 8 months before study entry was associated with increased risk of recurr

270 nts, a ventricular pre-excitation pattern at study entry was associated with markedly increased volta

271 of weight change per decade from midlife to study entry was greater for participants who developed i

272 tuximab treatment, the mean level of IAAs at study entry was markedly lower (P = 0.035) for patients

273 Choroidal thickness at study entry was significantly thicker in the study eyes

274 Median survival from study entry was similar for women (31 years; IQR 19-38)

275 increases in subjects who lost 6% or more of study entry weight.

276 mal cognition (n = 2587) or MCI (n = 482) at study entry were assessed every 6 months for incident de

277 ere LV dysfunction and greater remodeling at study entry were associated with less recovery.

278 worsening disability over the 2 y preceding study entry were calculated, and healthy controls (n = 1

279 participants with undetectable HIV-1 RNA at study entry were detectable (43 and 47 copies/mL) at wee

280 Baseline data at study entry were examined with respect to final outcome

281 trols with a history of head injury prior to study entry were excluded.

282 ersons diagnosed with IBS before the date of study entry were excluded.

283 lar cortical volume (p < 0.001, OR = 0.2) at study entry were found to predict the changing clinical

284 Women who reported dieting at study entry were heavier at study entry and gained more

285 an age 63 years [SD 11]) with CASI scores at study entry were included in the analysis, with a median

286 aive participants without liver cirrhosis at study entry were included.

287 Eyes without a vitreous hemorrhage at study entry were more likely to respond (odds ratio, 5.4

288 Prescription data at study entry were obtained from 404 participants in the R

289 Levels of sTNFRI and sTNFRII at study entry were quantified using enzyme-linked immunoso

290 ion therapy was initiated within 6 months of study entry were randomly assigned in a blinded 1:1 rati

291 ants who had never been intubated before the study entry were selected.

292 he risk factors for current atopic asthma at study entry were sensitization (adjusted odds ratio [OR]

293 and who did not report suicidal ideation at study entry were subsequently treated with citalopram hy

294 BsAg), anti-HCV, and serum HCV RNA levels at study entry were tested.

295 g stable doses of antiepileptic drugs before study entry, were enrolled in an expanded-access program

296 se rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory

297 iland, the majority of whom were on HAART at study entry, were prospectively followed semiannually fo

298 Plasma NT1 levels at study entry (when all participants were unimpaired) were

299 CRP concentrations were measured at study entry with a point-of-care assay using whole blood

300 was to minimize the percentage of persons at study entry with self-reported CHD (previous myocardial